ARCHIVES

Porter Softens Proposal To require SBIR Scores To Match R01s

This article is from The Cancer Letter archive.

Vol. 22 No. 30 | July 26, 1996

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

Rev/Vel/Dex Response Rate High In Phase I/II Study

January 25, 2008

Sarcoma Survivors At Risk Of Blood Clots, Study Finds

May 25, 2007

Blinatumomab Demonstrates High Response Rate in ALL

June 29, 2012

In Brief: Paul Rambaut Leaving NCI For NATO Position; Niederhuber New Cancer Commission Chairman

December 9, 1988

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

January 13, 2006